Louisa Sukkar1,2, Ben Talbot1, Min Jun1, Erika Dempsey1, Robert Walker3, Lai Hooi4, Alan Cass5, Meg Jardine1,2, Martin Gallagher1,2. 1. The George Institute for Global Health, Newtown, Australia. 2. Faculty of Medicine and Health, The University of Sydney, NSW, Australia. 3. Dunedin School of Medicine, University of Otago, Dunedin, New Zealand. 4. Hospital Sultanah Aminah, Johor Bahru, Malaysia. 5. Menzies School of Health Research, Casuarina, NT, Australia.
Abstract
BACKGROUND: There are limited studies on the effects of statins on outcomes in the moderate chronic kidney disease (CKD) population and their trajectory to end-stage kidney disease. OBJECTIVE: To examine the long-term effects of lipid-lowering therapy on all-cause mortality, cardiovascular morbidity, CKD progression, and socioeconomic well-being in Australian, New Zealand, and Malaysian SHARP (Study of Heart and Renal Protection) trial participants-a randomized controlled trial of a combination of simvastatin and ezetimibe, compared with placebo, for the reduction of cardiovascular events in moderate to severe CKD. DESIGN: Protocol for an extended prospective observational follow-up. SETTING: Australian, New Zealand, and Malaysian participating centers in patients with advanced CKD. PATIENTS: All SHARP trial participants alive at the final study visit. MEASUREMENTS: Primary outcomes were measured by participant self-report and verified by hospital administrative data. In addition, secondary outcomes were measured using a validated study questionnaire of health-related quality of life, a 56-item economic survey. METHODS: Participants were followed up with alternating face-to-face visits and telephone calls on a 6-monthly basis until 5 years following their final SHARP Study visit. In addition, there were 6-monthly follow-up telephone calls in between these visits. Data linkage to health registries in Australia, New Zealand, and Malaysia was also performed. RESULTS: The SHARP-Extended Review (SHARP-ER) cohort comprised 1136 SHARP participants with a median of 4.6 years of follow-up. Compared with all SHARP participants who originally participated in the Australian, New Zealand, and Malaysian regions, the SHARP-ER participants were younger (57.2 [48.3-66.4] vs 60.5 [50.3-70.7] years) with a lower proportion of men (61.5% vs 62.8%). There were a lower proportion of participants with hypertension (83.7% vs 85.0%) and diabetes (20.0% vs 23.5%). LIMITATIONS: As a long-term follow-up study, the surviving cohort of SHARP-ER is a selected group of the original study participants, which may limit the generalizability of the findings. CONCLUSION: The SHARP-ER study will contribute important evidence on the long-term outcomes of cholesterol-lowering therapy in patients with advanced CKD with a total of 10 years of follow-up. Novel analyses of the socioeconomic impact of CKD over time will guide resource allocation. TRIAL REGISTRATION: The SHARP trial was registered at ClinicalTrials.gov NCT00125593 and ISRCTN 54137607.
BACKGROUND: There are limited studies on the effects of statins on outcomes in the moderate chronic kidney disease (CKD) population and their trajectory to end-stage kidney disease. OBJECTIVE: To examine the long-term effects of lipid-lowering therapy on all-cause mortality, cardiovascular morbidity, CKD progression, and socioeconomic well-being in Australian, New Zealand, and Malaysian SHARP (Study of Heart and Renal Protection) trial participants-a randomized controlled trial of a combination of simvastatin and ezetimibe, compared with placebo, for the reduction of cardiovascular events in moderate to severe CKD. DESIGN: Protocol for an extended prospective observational follow-up. SETTING: Australian, New Zealand, and Malaysian participating centers in patients with advanced CKD. PATIENTS: All SHARP trial participants alive at the final study visit. MEASUREMENTS: Primary outcomes were measured by participant self-report and verified by hospital administrative data. In addition, secondary outcomes were measured using a validated study questionnaire of health-related quality of life, a 56-item economic survey. METHODS: Participants were followed up with alternating face-to-face visits and telephone calls on a 6-monthly basis until 5 years following their final SHARP Study visit. In addition, there were 6-monthly follow-up telephone calls in between these visits. Data linkage to health registries in Australia, New Zealand, and Malaysia was also performed. RESULTS: The SHARP-Extended Review (SHARP-ER) cohort comprised 1136 SHARP participants with a median of 4.6 years of follow-up. Compared with all SHARP participants who originally participated in the Australian, New Zealand, and Malaysian regions, the SHARP-ER participants were younger (57.2 [48.3-66.4] vs 60.5 [50.3-70.7] years) with a lower proportion of men (61.5% vs 62.8%). There were a lower proportion of participants with hypertension (83.7% vs 85.0%) and diabetes (20.0% vs 23.5%). LIMITATIONS: As a long-term follow-up study, the surviving cohort of SHARP-ER is a selected group of the original study participants, which may limit the generalizability of the findings. CONCLUSION: The SHARP-ER study will contribute important evidence on the long-term outcomes of cholesterol-lowering therapy in patients with advanced CKD with a total of 10 years of follow-up. Novel analyses of the socioeconomic impact of CKD over time will guide resource allocation. TRIAL REGISTRATION: The SHARP trial was registered at ClinicalTrials.gov NCT00125593 and ISRCTN 54137607.
Authors: Marcello Tonelli; Natasha Wiebe; Bruce Culleton; Andrew House; Chris Rabbat; Mei Fok; Finlay McAlister; Amit X Garg Journal: J Am Soc Nephrol Date: 2006-05-31 Impact factor: 10.121
Authors: T R Pedersen; L Wilhelmsen; O Faergeman; T E Strandberg; G Thorgeirsson; L Troedsson; J Kristianson; K Berg; T J Cook; T Haghfelt; J Kjekshus; T Miettinen; A G Olsson; K Pyörälä; H Wedel Journal: Am J Cardiol Date: 2000-08-01 Impact factor: 2.778
Authors: Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz Journal: N Engl J Med Date: 2005-07-21 Impact factor: 91.245
Authors: Ron T Gansevoort; Ricardo Correa-Rotter; Brenda R Hemmelgarn; Tazeen H Jafar; Hiddo J Lambers Heerspink; Johannes F Mann; Kunihiro Matsushita; Chi Pang Wen Journal: Lancet Date: 2013-05-31 Impact factor: 79.321
Authors: Bengt C Fellström; Alan G Jardine; Roland E Schmieder; Hallvard Holdaas; Kym Bannister; Jaap Beutler; Dong-Wan Chae; Alejandro Chevaile; Stuart M Cobbe; Carola Grönhagen-Riska; José J De Lima; Robert Lins; Gert Mayer; Alan W McMahon; Hans-Henrik Parving; Giuseppe Remuzzi; Ola Samuelsson; Sandor Sonkodi; D Sci; Gultekin Süleymanlar; Dimitrios Tsakiris; Vladimir Tesar; Vasil Todorov; Andrzej Wiecek; Rudolf P Wüthrich; Mattis Gottlow; Eva Johnsson; Faiez Zannad Journal: N Engl J Med Date: 2009-03-30 Impact factor: 91.245
Authors: Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins Journal: Lancet Date: 2011-06-12 Impact factor: 79.321
Authors: Yun-Hee Jeon; Beverley Essue; Stephen Jan; Robert Wells; Judith A Whitworth Journal: BMC Health Serv Res Date: 2009-10-09 Impact factor: 2.655
Authors: Suzanne M Lloyd; David J Stott; Anton J M de Craen; Patricia M Kearney; Naveed Sattar; Ivan Perry; Christopher J Packard; Andrew Briggs; Laura Marchbank; Harry Comber; J Wouter Jukema; Rudi G J Westendorp; Stella Trompet; Brendan M Buckley; Ian Ford Journal: PLoS One Date: 2013-09-02 Impact factor: 3.240
Authors: Roy O Mathew; Robert S Rosenson; Radmila Lyubarova; Rafia Chaudhry; Salvatore P Costa; Sripal Bangalore; Mandeep S Sidhu Journal: Cardiovasc Drugs Ther Date: 2021-06 Impact factor: 3.727